TY - JOUR
T1 - Rationale and design of the NO-PARTY trial
T2 - Near-zero fluoroscopic exposure during catheter ablation of supraventricular arrhythmias in young patients
AU - Casella, Michela
AU - Dello Russo, Antonio
AU - Pelargonio, Gemma
AU - Bongiorni, Maria Grazia
AU - Del Greco, Maurizio
AU - Piacenti, Marcello
AU - Andreassi, Maria Grazia
AU - Santangeli, Pasquale
AU - Bartoletti, Stefano
AU - Moltrasio, Massimo
AU - Fassini, Gaetano
AU - Marini, Massimiliano
AU - Di Cori, Andrea
AU - Di Biase, Luigi
AU - Fiorentini, Cesare
AU - Zecchi, Paolo
AU - Natale, Andrea
AU - Picano, Eugenio
AU - Tondo, Claudio
PY - 2012/10
Y1 - 2012/10
N2 - Introduction Radiofrequency catheter ablation is the mainstay of therapy for supraventricular tachyarrhythmias. Conventional radiofrequency catheter ablation requires the use of fluoroscopy, thus exposing patients to ionising radiation. The feasibility and safety of non-fluoroscopic radiofrequency catheter ablation has been recently reported in a wide range of supraventricular tachyarrhythmias using the EnSite NavX™ mapping system. The NO-PARTY is a multi-centre, randomised controlled trial designed to test the hypothesis that catheter ablation of supraventricular tachyarrhythmias guided by the EnSite NavX™ mapping system results in a clinically significant reduction in exposure to ionising radiation compared with conventional catheter ablation. Methods The study will randomise 210 patients undergoing catheter ablation of supraventricular tachyarrhythmias to either a conventional ablation technique or one guided by the EnSite NavX™ mapping system. The primary end-point is the reduction of the radiation dose to the patient. Secondary end-points include procedural success, reduction of the radiation dose to the operator, and a cost-effectiveness analysis. In a subgroup of patients, we will also evaluate the radiobiological effectiveness of dose reduction by assessing acute chromosomal DNA damage in peripheral blood lymphocytes. Conclusions NO-PARTY will determine whether radiofrequency catheter ablation of supraventricular tachyarrhythmias guided by the EnSite NavX™ mapping system is a suitable and cost-effective approach to achieve a clinically significant reduction in ionising radiation exposure for both patient and operator.
AB - Introduction Radiofrequency catheter ablation is the mainstay of therapy for supraventricular tachyarrhythmias. Conventional radiofrequency catheter ablation requires the use of fluoroscopy, thus exposing patients to ionising radiation. The feasibility and safety of non-fluoroscopic radiofrequency catheter ablation has been recently reported in a wide range of supraventricular tachyarrhythmias using the EnSite NavX™ mapping system. The NO-PARTY is a multi-centre, randomised controlled trial designed to test the hypothesis that catheter ablation of supraventricular tachyarrhythmias guided by the EnSite NavX™ mapping system results in a clinically significant reduction in exposure to ionising radiation compared with conventional catheter ablation. Methods The study will randomise 210 patients undergoing catheter ablation of supraventricular tachyarrhythmias to either a conventional ablation technique or one guided by the EnSite NavX™ mapping system. The primary end-point is the reduction of the radiation dose to the patient. Secondary end-points include procedural success, reduction of the radiation dose to the operator, and a cost-effectiveness analysis. In a subgroup of patients, we will also evaluate the radiobiological effectiveness of dose reduction by assessing acute chromosomal DNA damage in peripheral blood lymphocytes. Conclusions NO-PARTY will determine whether radiofrequency catheter ablation of supraventricular tachyarrhythmias guided by the EnSite NavX™ mapping system is a suitable and cost-effective approach to achieve a clinically significant reduction in ionising radiation exposure for both patient and operator.
KW - Atrioventricular nodal reentrant tachycardia
KW - accessory pathway
KW - electroanatomical mapping
KW - radiation exposure
KW - radiofrequency catheter ablation
UR - http://www.scopus.com/inward/record.url?scp=84866370348&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866370348&partnerID=8YFLogxK
U2 - 10.1017/S1047951112000042
DO - 10.1017/S1047951112000042
M3 - Article
C2 - 22325367
AN - SCOPUS:84866370348
SN - 1047-9511
VL - 22
SP - 539
EP - 546
JO - Cardiology in the Young
JF - Cardiology in the Young
IS - 5
ER -